182 related articles for article (PubMed ID: 8913266)
21. Physiochemical aspects of tubulin-interacting antimitotic drugs.
Correia JJ; Lobert S
Curr Pharm Des; 2001 Sep; 7(13):1213-28. PubMed ID: 11472263
[TBL] [Abstract][Full Text] [Related]
22. Effects of antimitotic agents on tubulin-nucleotide interactions.
Correia JJ
Pharmacol Ther; 1991 Nov; 52(2):127-47. PubMed ID: 1818332
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the interaction of cryptophycin 1 with tubulin: binding in the Vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction.
Bai R; Schwartz RE; Kepler JA; Pettit GR; Hamel E
Cancer Res; 1996 Oct; 56(19):4398-406. PubMed ID: 8813133
[TBL] [Abstract][Full Text] [Related]
24. Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin.
Mitra A; Sept D
Biochemistry; 2004 Nov; 43(44):13955-62. PubMed ID: 15518544
[TBL] [Abstract][Full Text] [Related]
25. Rhizoxin binding to tubulin at the maytansine-binding site.
Takahashi M; Iwasaki S; Kobayashi H; Okuda S; Murai T; Sato Y
Biochim Biophys Acta; 1987 Dec; 926(3):215-23. PubMed ID: 3120782
[TBL] [Abstract][Full Text] [Related]
26. Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules.
Himes RH
Pharmacol Ther; 1991; 51(2):257-67. PubMed ID: 1784631
[TBL] [Abstract][Full Text] [Related]
27. Localization of the colchicine-binding site of tubulin.
Uppuluri S; Knipling L; Sackett DL; Wolff J
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11598-602. PubMed ID: 8265596
[TBL] [Abstract][Full Text] [Related]
28. Microtubules as drug receptors: pharmacological properties of microtubule protein.
Wilson L
Ann N Y Acad Sci; 1975 Jun; 253():213-31. PubMed ID: 1096718
[No Abstract] [Full Text] [Related]
29. Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1.
Panda D; Himes RH; Moore RE; Wilson L; Jordan MA
Biochemistry; 1997 Oct; 36(42):12948-53. PubMed ID: 9335554
[TBL] [Abstract][Full Text] [Related]
30. The mechanism of action of colchicine. Colchicine binding properties of sea urchin sperm tail outer doublet tubulin.
Wilson L; Meza I
J Cell Biol; 1973 Sep; 58(3):709-19. PubMed ID: 4747924
[TBL] [Abstract][Full Text] [Related]
31. Analysis of drug-tubulin interaction by trypsin cleavage: comparison for colchicine, podophyllotoxin, griseofulvin, vinblastine and taxol.
Wandosell F; Villanueva N; Serrano L; Avila J
Comp Biochem Physiol B; 1986; 85(3):635-8. PubMed ID: 2878792
[TBL] [Abstract][Full Text] [Related]
32. [Inhibitors of tubulin assembly: specially on rhizoxin-maytansine site ligands].
Iwasaki S
Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1742-52. PubMed ID: 8210422
[No Abstract] [Full Text] [Related]
33. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
Jordan A; Hadfield JA; Lawrence NJ; McGown AT
Med Res Rev; 1998 Jul; 18(4):259-96. PubMed ID: 9664292
[TBL] [Abstract][Full Text] [Related]
34. Interaction of phomopsin A with porcine brain tubulin. Inhibition of tubulin polymerization and binding at a rhizoxin binding site.
Li Y; Kobayashi H; Tokiwa Y; Hashimoto Y; Iwasaki S
Biochem Pharmacol; 1992 Jan; 43(2):219-24. PubMed ID: 1739410
[TBL] [Abstract][Full Text] [Related]
35. Caulerpenyne binding to tubulin: structural modifications by a non conventional pharmacological agent.
Bourdron J; Barbier P; Allegro D; Villard C; Lafitte D; Commeiras L; Parrain JL; Peyrot V
Med Chem; 2009 Mar; 5(2):182-90. PubMed ID: 19275717
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic selectivity of vinca alkaloids: a role for guanosine 5'-triphosphate?
Houghton PJ; Houghton JA; Bowman LC; Hazelton BJ
Anticancer Drug Des; 1987 Oct; 2(2):165-79. PubMed ID: 3329524
[TBL] [Abstract][Full Text] [Related]
37. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.
Li L; Jiang S; Li X; Liu Y; Su J; Chen J
Eur J Med Chem; 2018 May; 151():482-494. PubMed ID: 29649743
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity.
Bai R; Roach MC; Jayaram SK; Barkoczy J; Pettit GR; Ludueña RF; Hamel E
Biochem Pharmacol; 1993 Apr; 45(7):1503-15. PubMed ID: 8471072
[TBL] [Abstract][Full Text] [Related]
40. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents.
Shi Q; Chen K; Morris-Natschke SL; Lee KH
Curr Pharm Des; 1998 Jun; 4(3):219-48. PubMed ID: 10197041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
